{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.1"},{"groupId":"OG001","value":"42.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"The immune response to tetanus toxoid adsorbed booster vaccine was measured in serum samples immediately prior to and 4 weeks after vaccine administration. The tetanus antibody test was an ELISA that used tetanus toxoid as a capturing reagent and alkaline phosphatase-conjugated anti-human IgG (γ) for detection. For patients with pre-vaccination tetanus antibody titers \\< 0.1 IU/mL, a positive immune response was defined as an antibody titer ≥ 0.2 IU/mL. For patients with pre-vaccination tetanus antibody titers ≥ 0.1 IU/mL, a positive immune response to the booster immunization was defined as a 4-fold increase in antibody titer.","groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG000","title":"Rituximab + Methotrexate (Group A)"},{"description":"Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG001","title":"Methotrexate (Group B)"}],"paramType":"NUMBER","populationDescription":"Immune response per-protocol population: Group A - All patients randomized to Group A who received any rituximab infusion and any vaccine and had pre-vaccination and 4-week post-vaccination blood samples. Group B - All patients randomized to Group B who received any vaccine and had pre-vaccination and 4-week post-vaccination blood samples.","reportingStatus":"POSTED","timeFrame":"Week 24 to Week 28 for Group A and Day 1 to Week 4 for Group B","title":"Percentage of Patients With a Positive Immune Response to Tetanus Toxoid Adsorbed Booster Vaccine","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}